By Vivien Marx

Armed with a $110,000 Small Business Innovation Research grant from the National Human Genome Research Institute, Geospiza plans to collaborate with the Mayo Clinic to explore how to develop software systems that will push second-generation sequencing closer to use as a cancer diagnostics tool.

"The plan is to test the feasibility of developing new approaches to detecting sequence variants at low levels," Geospiza CEO Todd Smith told BioInform.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.